All In Biotech

Drug Trial Radar · NCT06217120

Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

Reversing Microvascular Dysfunction in Heart Failure With Ejection Fraction > 40% Using Colchicine (The COL-Micro-HF Study)

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Nov 6, 2026

Primary completion

Apr 2027

Study completion May 2028

Sponsor

Lead sponsor
Montreal Heart InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Heart and Stroke Foundation of Canada; Centre hospitalier de l'Université de Montréal (CHUM)
First posted
Jan 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the impact of colchicine on the change in myocardial flow reserve (MFR), a marker for coronary microvascular dysfunction (CMD), compared to a matched placebo in patients with heart failure and ejection fraction above 40% (including patients with improved EF).

Conditions

  • Heart Failure With Preserved Ejection Fraction
  • Microvascular Coronary Artery Disease

Interventions

  • ColchicineDrug

    Colchicine 0.6 mg once daily

  • PlaceboDrug

    Placebo once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in myocardial flow reserve (MFR) between baseline and six monthsTime frame: Baseline and 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre de recherche du Centre hospitalier de l'Université de Montréal

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.